Clinical trials: Healthy Male Subjects
Thromboembolic Disorders
A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants
Researchers were looking for another way to treat people with a blood clot in their veins. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it behaves.
- Trial name
- NCT04720092
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Drug Drug Interaction, Healthy
Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470
A study on whether ACT-1014-6470 has an effect on how the body takes up, distributes and gets rid of omeprazole and midazolam in healthy male subjects
- Trial name
- NCT05123820
- Testing
- Treatment period A, Treatment period B
- Where
- Czechia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Metabolic Processes
A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178
The study aims to assess the routes and the extent of metabolism and excretion of YM178 after a single dose of 14C-radiolabeled YM178 administered as a drinking solution in healthy male volunteers.
- Trial name
- NCT01651312
- Testing
- 14C-labeled YM178
- Where
- Netherlands
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy
A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition
The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20 mg manufactured by OHM Laboratories with…
- Trial name
- NCT01079065
- Testing
- Famotidine
- Where
- India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Diabetes Mellitus, Type 2
First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.
The aim of this study is to assess how safe the study drug is and how well a participant tolerates it after a single oral (taken by mouth) dose.
- Trial name
- NCT03617081
- Testing
- NNC0113-2023
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Adult Male and Female Volunteers
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
- Trial name
- NCT04341077
- Testing
- SHR3162
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
To evaluate the safety, tolerability, and pharmacokinetics of pomalidomide administered orally once a day for 5 days, at daily doses of 0.5 mg, 1 mg, or 2 mg.
- Trial name
- NCT01474330
- Testing
- Pomalidomide
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy Males 65-75 Yrs Old
Determination of Protein Requirement in Elderly Male Subjects 65-75 Yrs Old.
Minimal data are available on protein requirements throughout the lifespan. Currently available recommendations are based on nitrogen balance data. The limitations of the nitrogen balance method have been well described.
- Trial name
- NCT01943266
- Testing
- protein intake
- Where
- Canada
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Healthy
A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants
This study will look at how a drug (tucatinib) leaves the body and what happens to tucatinib while it is still in the body. Healthy participants will get one dose of tucatinib by mouth.
- Trial name
- NCT03758339
- Testing
- tucatinib
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cascadian Therapeutics Inc.
Healthy
A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects
This is a double-blind, placebo-controlled, multiple oral dose study to evaluate safety, tolerability, and pharmacokinetic of KBP-7072 in healthy subjects.
- Trial name
- NCT04532957
- Testing
- KBP-7072
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- KBP Biosciences
Invasive Aspergillosis
F901318 Single Ascending Dose Study in Healthy Male Volunteers
F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.
- Trial name
- NCT02142153
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Healthy Subjects
Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606
This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of [14C]-SKI-606 in healthy male subjects.
- Trial name
- NCT00757341
- Testing
- SKI-606
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neurological Pathology, Healthy Subjects
[18F]-F13640 as a New Brain Radiopharmaceutical
This clinical assay is designed to validate that [18F]F13640 as a radiotracer of 5-HT1A functional receptors. A first group of healthy subjects underwent a PET scan with arterial blood sampling to determine the kinetic model of…
- Trial name
- F13640 (NCT03347331)
- Testing
- [18F]F13640
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumor
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
1. Investigational Product 1. Imatinib mesylate tablet 400 mg 2. Glivec film-coated tablet 100 mg (Comparator) 2. Expected target disease 1. chronic myeloid leukemia 2. Gastrointestinal stromal tumors 3.
- Trial name
- NCT01751919
- Testing
- Imatinib mesylate tablet 400 mg, 1 Tablet, Glivec film-coated tablet 100 mg, 4 Tablets
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Healthy Subjects, Pharmacokinetics of ASP3652
A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652
The study investigates how safe ASP3652 is and how well it is tolerated when taken as multiple doses. The study also assesses how quickly and to what extent it is absorbed and eliminated from the body.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP3652, Pharmacodynamics of ASP3652
- Trial name
- NCT02243657
- Testing
- ASP3652
- Where
- Netherlands
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Cocaine Dependence
Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects
This is the first study to be conducted in humans for RTI-336, a new chemical entity, with evaluations focusing on the safety, tolerability, and pharmacokinetics of RTI-336 following administration of single, oral doses.
- Trial name
- NCT00808119
- Testing
- RTI-336 (CTDP 31862)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- RTI International
Renal Insufficiency
A Pharmacokinetics and Safety Study of Azvudine Tablets in Subjects With Mild-To-Moderate GFR Decline in Renal Insufficiency and in Healthy Subjects
Azvudine(FNC)，a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's compliance.
- Trial name
- NCT07001436
- Testing
- Azvudine tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Pharmacokinetics of ASP3652, Pharmacodynamics of ASP3652
A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects
The purpose of this study is to evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of multiple doses of ASP3652 in healthy young Caucasian male subjects.
- Conditions
- Pharmacokinetics of ASP3652, Pharmacodynamics of ASP3652, Healthy Subjects
- Trial name
- NCT02034734
- Testing
- ASP3652
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Drug-Drug Interaction
Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects
The purpose of this study is to evaluate the Drug interaction and safety of Fimasartan/Amlodipine and Hydrochlorothiazide in Healthy Male volunteers.
- Trial name
- NCT03390465
- Testing
- Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Pain
A Trial of HRS4800 Tables in Healthy Male Subjects
This is a single-site study to evaluate the safety, tolerability and pharmacokinetics (PK) of single dose administration of HRS4800, and the effect of food on the PK of HRS4800 in healthy male subjects.
- Trial name
- NCT04573036
- Testing
- HRS4800 tablets
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.